Shares of rare disease drug developer X4 Pharmaceuticals took a battering after it said it will restructure its workforce and ...

Nearly one year after winning an FDA drug approval to treat an ultra-rare disease, X4 Pharmaceuticals is making layoffs that ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

X4 Pharmaceuticals, Inc.’s XFOR share price has dipped by 10.83%, which has investors questioning if this is right time to ...

A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

Which Treatment for Breast Cancer Results in Better QoL? Compared with endocrine therapy, radiotherapy was associated with a smaller reduction in health-related quality-of-life in older patients ...